KPJ Healthcare Berhad Croissance future

Future contrôle des critères 1/6

KPJ Healthcare Berhad devrait augmenter ses bénéfices et son chiffre d'affaires de 8.7% et de 5.9% par an respectivement. Le BPA devrait croître de de 6.8% par an. Le rendement des capitaux propres devrait être 12.7% dans 3 ans.

Informations clés

8.7%

Taux de croissance des bénéfices

6.8%

Taux de croissance du BPA

Healthcare croissance des bénéfices	2.4%
Taux de croissance des recettes	5.9%
Rendement futur des capitaux propres	12.7%
Couverture par les analystes	Good
Dernière mise à jour	09 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

KPJ Healthcare Berhad (KLSE:KPJ) Shares Could Be 37% Below Their Intrinsic Value Estimate

Nov 07

Is There An Opportunity With KPJ Healthcare Berhad's (KLSE:KPJ) 33% Undervaluation?

Jun 24

KPJ Healthcare Berhad's (KLSE:KPJ) Dividend Will Be MYR0.01

Jun 02

Here's Why KPJ Healthcare Berhad (KLSE:KPJ) Has Caught The Eye Of Investors

Mar 25

KPJ Healthcare Berhad (KLSE:KPJ) Shares Could Be 37% Below Their Intrinsic Value Estimate

Mar 11

KPJ Healthcare Berhad's (KLSE:KPJ) Shares May Have Run Too Fast Too Soon

Feb 14

Is KPJ Healthcare Berhad (KLSE:KPJ) Using Too Much Debt?

Jan 23

Returns At KPJ Healthcare Berhad (KLSE:KPJ) Appear To Be Weighed Down

Jan 09

KPJ Healthcare Berhad's (KLSE:KPJ) Intrinsic Value Is Potentially 31% Above Its Share Price

Jun 06

These 4 Measures Indicate That KPJ Healthcare Berhad (KLSE:KPJ) Is Using Debt Reasonably Well

May 03

KPJ Healthcare Berhad (KLSE:KPJ) Has More To Do To Multiply In Value Going Forward

Mar 07

KPJ Healthcare Berhad's (KLSE:KPJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 20

KPJ Healthcare Berhad's (KLSE:KPJ) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31

KPJ Healthcare Berhad (KLSE:KPJ) Is Increasing Its Dividend To MYR0.0055

Sep 15

KPJ Healthcare Berhad's (KLSE:KPJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Sep 01

Capital Allocation Trends At KPJ Healthcare Berhad (KLSE:KPJ) Aren't Ideal

Aug 11

The Consensus EPS Estimates For KPJ Healthcare Berhad (KLSE:KPJ) Just Fell Dramatically

May 30

Prévisions de croissance des bénéfices et des revenus

KLSE:KPJ - Estimations futures des analystes et données financières antérieures (MYR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	4,251	363	601	745	13
12/31/2025	3,989	332	481	705	14
12/31/2024	3,727	295	462	697	13
6/30/2024	3,657	304	370	639	N/A
3/31/2024	3,512	303	350	591	N/A
12/31/2023	3,419	281	417	658	N/A
9/30/2023	3,254	275	364	583	N/A
6/30/2023	3,128	235	324	548	N/A
3/31/2023	3,042	211	282	527	N/A
12/31/2022	2,868	179	226	460	N/A
9/30/2022	2,792	122	284	555	N/A
6/30/2022	2,692	84	250	485	N/A
3/31/2022	2,626	64	225	470	N/A
12/31/2021	2,590	55	195	412	N/A
9/30/2021	2,560	58	122	368	N/A
6/30/2021	2,495	79	128	386	N/A
3/31/2021	2,338	85	93	307	N/A
12/31/2020	2,397	110	95	337	N/A
9/30/2020	1,853	169	160	415	N/A
6/30/2020	2,138	182	110	446	N/A
3/31/2020	2,523	211	132	535	N/A
12/31/2019	2,738	211	177	581	N/A
9/30/2019	3,581	180	148	604	N/A
6/30/2019	3,483	176	167	560	N/A
3/31/2019	3,424	176	174	543	N/A
12/31/2018	3,366	179	131	518	N/A
9/30/2018	3,279	188	3	381	N/A
6/30/2018	3,246	177	-81	296	N/A
3/31/2018	3,224	168	N/A	359	N/A
12/31/2017	3,180	166	N/A	362	N/A
9/30/2017	3,040	161	N/A	279	N/A
6/30/2017	3,018	162	N/A	391	N/A
3/31/2017	3,005	160	N/A	239	N/A
12/31/2016	2,970	154	N/A	143	N/A
9/30/2016	2,978	124	N/A	187	N/A
6/30/2016	2,933	130	N/A	115	N/A
3/31/2016	2,882	136	N/A	192	N/A
12/31/2015	2,848	135	N/A	189	N/A
9/30/2015	2,862	158	N/A	338	N/A
6/30/2015	2,798	149	N/A	322	N/A
3/31/2015	2,746	147	N/A	339	N/A
12/31/2014	2,639	143	N/A	319	N/A
9/30/2014	2,556	126	N/A	270	N/A
6/30/2014	2,464	117	N/A	174	N/A
3/31/2014	2,389	108	N/A	140	N/A
12/31/2013	2,332	103	N/A	144	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de KPJ ( 8.7% par an) est supérieure au taux d'épargne ( 3.6% ).

Bénéfices vs marché: Les bénéfices de KPJ ( 8.7% par an) devraient croître plus lentement que le marché MY ( 11% par an).

Croissance élevée des bénéfices: Les bénéfices de KPJ devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de KPJ ( 5.9% par an) devrait croître plus lentement que le marché de MY ( 6.1% par an).

Croissance élevée des revenus: Le chiffre d'affaires de KPJ ( 5.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de KPJ devrait être faible dans 3 ans ( 12.7 %).

KPJ Healthcare Berhad Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 7.4% to RM1.93

Price target increased by 8.3% to RM1.72

Price target increased by 8.6% to RM1.48

Consensus EPS estimates increase by 25%

Price target increased by 8.7% to RM1.23

Consensus EPS estimates increase by 30%

Recent updates

KPJ Healthcare Berhad (KLSE:KPJ) Shares Could Be 37% Below Their Intrinsic Value Estimate

KPJ Healthcare Berhad's (KLSE:KPJ) Price Is Out Of Tune With Earnings

KPJ Healthcare Berhad (KLSE:KPJ) Has Affirmed Its Dividend Of MYR0.01

Second quarter dividend of RM0.01 announced

KPJ Healthcare Berhad to Report Q2, 2024 Results on Aug 28, 2024

Second quarter 2024 earnings: Revenues exceed analyst expectations

Returns Are Gaining Momentum At KPJ Healthcare Berhad (KLSE:KPJ)

Do KPJ Healthcare Berhad's (KLSE:KPJ) Earnings Warrant Your Attention?

Is There An Opportunity With KPJ Healthcare Berhad's (KLSE:KPJ) 33% Undervaluation?

Price target increased by 7.4% to RM1.93

KPJ Healthcare Berhad Appoints Encik Mohd Khairul Izzad Bin Mohammed Shamsudin as Chief Financial Officer, Effective June 10, 2024

KPJ Healthcare Berhad's (KLSE:KPJ) Dividend Will Be MYR0.01

First quarter dividend of RM0.01 announced

First quarter 2024 earnings: EPS misses analyst expectations

KPJ Healthcare Berhad, Annual General Meeting, Jun 26, 2024

Here's Why KPJ Healthcare Berhad (KLSE:KPJ) Has Caught The Eye Of Investors

KPJ Healthcare Berhad Announces Resignation of Md Arif Bin Mahmood as Non Independent and Non Executive Chairman, Effective April 1, 2024

KPJ Healthcare Berhad (KLSE:KPJ) Shares Could Be 37% Below Their Intrinsic Value Estimate

Price target increased by 8.3% to RM1.72

Full year 2023 earnings: EPS and revenues exceed analyst expectations

KPJ Healthcare Berhad's (KLSE:KPJ) Shares May Have Run Too Fast Too Soon

Is KPJ Healthcare Berhad (KLSE:KPJ) Using Too Much Debt?

Returns At KPJ Healthcare Berhad (KLSE:KPJ) Appear To Be Weighed Down

Upcoming dividend of RM0.013 per share at 3.0% yield

Price target increased by 8.6% to RM1.48

KPJ Healthcare Berhad to Report Q3, 2023 Results on Nov 28, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

KPJ Healthcare Berhad Announces Single Tier Special Dividend for the Financial Year Ending 31 December 2023

KPJ Healthcare Berhad Announces Appointment of Keh Ching Tyng as Joint Secretary

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kpj Healthcare Berhad Announces Appointment of Mr. Chin Keat Chyuan as President, Effective 1 September 2023

KPJ Healthcare Berhad's (KLSE:KPJ) Intrinsic Value Is Potentially 31% Above Its Share Price

KPJ Healthcare Berhad Declares Interim Dividend for the Year Ended December 31, 2023, Payable on July 4, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

Now 22% undervalued

These 4 Measures Indicate That KPJ Healthcare Berhad (KLSE:KPJ) Is Using Debt Reasonably Well

Full year 2022 earnings released: EPS: RM0.04 (vs RM0.013 in FY 2021)

Now 23% undervalued

Now 22% undervalued

Now 21% undervalued

KPJ Healthcare Berhad (KLSE:KPJ) Has More To Do To Multiply In Value Going Forward

Consensus EPS estimates increase by 25%

Price target increased by 8.7% to RM1.23

KPJ Healthcare Berhad's (KLSE:KPJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: EPS and revenues exceed analyst expectations

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Financial Year End December 31, 2023, Payable on April 14, 2023

Now 21% undervalued

KPJ Healthcare Berhad's (KLSE:KPJ) Intrinsic Value Is Potentially 26% Above Its Share Price

Upcoming dividend of RM0.01 per share

Consensus EPS estimates increase by 30%

Price target increased to RM1.07

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Financial Year Ended December 31, 2022, Payable on December 28, 2022

KPJ Healthcare Berhad (KLSE:KPJ) Is Increasing Its Dividend To MYR0.0055

KPJ Healthcare Berhad Appoints Encik Hisham Bin Zainal Mokhtar as Independent and Non Executive Member of Risk Committee

KPJ Healthcare Berhad Announces Resignation of Mohd Shukrie Bin Mohd Salleh as Managing Director

KPJ Healthcare Berhad Announces Resignation of Mohd Shukrie Bin Mohd Salleh as Managing Director

KPJ Healthcare Berhad's (KLSE:KPJ) Shareholders Will Receive A Bigger Dividend Than Last Year

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Fiscal Year Ending December 31, 2022, Payable on 21 October 2022

KPJ Healthcare Berhad Announces the Resignation of TEH PENG PENG as Joint Secretary

KPJ Healthcare Berhad Appoints Nantha Kumar Subramanian as Its New Chief Digital Officer

KPJ Healthcare Berhad Appoints Lee Lai Fan as Independent and Non Executive Director

KPJ Healthcare Berhad Announces Retirement of Puan Lydia Anne Abraham as Independent and Non Executive Director

Consensus EPS estimates fall by 17%

High number of new directors

Now 22% undervalued after recent price drop

KPJ Healthcare Berhad Announces Single Tier Interim Dividend for the Financial Year Ending December 31, 2022, Payable on 29 Jul 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind